These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 20118030)

  • 1. Managing neutropenia in older patients with cancer receiving chemotherapy in a community setting.
    Flores IQ; Ershler W
    Clin J Oncol Nurs; 2010 Feb; 14(1):81-6. PubMed ID: 20118030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegfilgrastim.
    Curran MP; Goa KL
    Drugs; 2002; 62(8):1207-13; discussion 1214-5. PubMed ID: 12010086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.
    Crawford J
    Pharmacotherapy; 2003 Aug; 23(8 Pt 2):15S-19S. PubMed ID: 12921218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
    Crawford J
    Semin Oncol; 2003 Aug; 30(4 Suppl 13):24-30. PubMed ID: 14508717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutropenia-Associated Outcomes in Patients With Breast Cancer Receiving Myelosuppressive Chemotherapy With Reduced Doses of Pegfilgrastim.
    Moore DC; Gebru T; Pellegrino A; Fasan A; Patel J; Ringley JT
    J Pharm Pract; 2020 Dec; 33(6):779-783. PubMed ID: 30917723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia.
    Biganzoli L; Untch M; Skacel T; Pico JL
    Semin Oncol; 2004 Jun; 31(3 Suppl 8):27-34. PubMed ID: 15181606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on pegfilgrastim in chemotherapy-induced neutropenia.
    Frampton JE; Keating GM
    BioDrugs; 2005; 19(6):405-7. PubMed ID: 16392893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.
    Weycker D; Malin J; Barron R; Edelsberg J; Kartashov A; Oster G
    Am J Clin Oncol; 2012 Jun; 35(3):267-74. PubMed ID: 21378538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
    Lane SW; Crawford J; Kenealy M; Cull G; Seymour JF; Prince HM; Marlton P; Gill D; Mollee PN
    Leuk Lymphoma; 2006 Sep; 47(9):1813-7. PubMed ID: 17064993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients.
    Molineux G
    Anticancer Drugs; 2003 Apr; 14(4):259-64. PubMed ID: 12679729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.
    Almenar D; Mayans J; Juan O; Bueno JM; Lopez JI; Frau A; Guinot M; Cerezuela P; Buscalla EG; Gasquet JA; Sanchez J
    Eur J Cancer Care (Engl); 2009 May; 18(3):280-6. PubMed ID: 19076208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience.
    Renwick W; Pettengell R; Green M
    BioDrugs; 2009; 23(3):175-86. PubMed ID: 19627169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
    Green MD; Koelbl H; Baselga J; Galid A; Guillem V; Gascon P; Siena S; Lalisang RI; Samonigg H; Clemens MR; Zani V; Liang BC; Renwick J; Piccart MJ;
    Ann Oncol; 2003 Jan; 14(1):29-35. PubMed ID: 12488289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
    Blackwell K; Donskih R; Jones CM; Nixon A; Vidal MJ; Nakov R; Singh P; Schaffar G; Gascón P; Harbeck N
    Oncologist; 2016 Jul; 21(7):789-94. PubMed ID: 27091420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study.
    Link H; Illerhaus G; Martens UM; Salar A; Depenbusch R; Köhler A; Engelhardt M; Mahlmann S; Zaiss M; Lammerich A; Bias P; Buchner A
    Support Care Cancer; 2021 May; 29(5):2519-2527. PubMed ID: 32944800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
    Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W;
    Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maximizing the outcomes in cancer patients receiving chemotherapy through optimal use of colony-stimulating factor.
    Mucenski JW; Shogan JE
    J Manag Care Pharm; 2003; 9(2 Suppl):10-4. PubMed ID: 14613339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
    Lyman G; Lalla A; Barron R; Dubois RW
    Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-per-cycle pegfilgrastim versus daily filgrastim in pediatric patients with Ewing sarcoma.
    Wendelin G; Lackner H; Schwinger W; Sovinz P; Urban C
    J Pediatr Hematol Oncol; 2005 Aug; 27(8):449-51. PubMed ID: 16096530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.